孢子丝菌病药敏和治疗进展  

Advances in the susceptibility testing of Sporothrix schenckii and treatment of sporotrichosis

作　　者：蔡晴[1] 李珊山[1] 刘维达[2] 

机构地区：[1]吉林大学第一医院皮肤科,长春130021 [2]中国医学科学院北京协和医学院皮肤病研究所

出　　处：《国际皮肤性病学杂志》2010年第1期12-14,共3页International Journal of Dermatology and Venereology

基　　金：吉林省科技厅资助项目（200705139）

摘　　要：孢子丝菌病是一种深部真菌病，其致病菌申克孢子丝菌为一种双相真菌，双相真菌的体外药敏试验至今仍无统一标准。饱和碘化钾溶液、伊曲康唑、特比萘芬为治疗孢子丝菌病的常用药物，临床中选择合适的抗真菌药物对治疗此病具有重要意义。体外药敏试验是评价抗真菌药物活性的重要方法，也是选择药物的依据之一。Sporotrichosis is a subcutaneous infection caused by Sporothrix schenckii, a dimorphic fungus. No unified standard is available at present for in vitro susceptibility testing of dimorphic fungi. Although saturated solution of potassium iodide, itraconazole and terbinafine have been commonly used in the treatment of sporotrichosis for many years, it is still essential to choose appropriate antifungals. In vitro susceptibility test is not only an important means to the estimate of antifungal activity but also a basis for drug selection.

关 键 词：孢子丝菌病 孢子丝菌属 微生物敏感性试验 治疗 

分 类 号：R756[医药卫生—皮肤病学与性病学]